PATENT CLAIM ANALYSIS

Application Number: 15938409
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["546", "014000"]

Abstract:
A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK 1  receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Claim (Index 4):
The method of  claim 3 , further comprising administering to the patient an effective amount of at least one anti-depressant agent and/or at least one anti-anxiety agent.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 1.19048
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13245403', '12750420', '11432133', '11653558', '10741056']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8132175333726891
- 35 USC 102 Novelty (BERT): 0.5260576482625446
- Combined Prediction Score: 0.7845015448616747
- Mean Citation Score: 343.390956
- Max Citation Score: 362.47183
- Similarity Product: 261.352759981004

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test